Alex J. Coulter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex J. Coulter has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Arun Kumar Tiwari
Tanenbaum Centre for Pharmacogenetics, Neurogenetics Section, Molecular Brain Sciences Research Department, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
2 shared publications - Clement C. Zai
Centre for Addiction & Mental Health
2 shared publications - James L. Kennedy
CAMH, University of Toronto
2 shared publications - Megana Thamilselvan
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
2 shared publications - Anashe Shahmirian
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
1 shared publication - Daniel J. Mueller
University of Toronto
1 shared publication
Latest Publications
- 4 June 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (9) , 703-711
Distribution of Cytochrome P450 Metabolizer Status and Allelic Variants in Individuals with Mental Health Disorders in Ontario, Canada: Répartition du statut métabolique du cytochrome P450 et des variantes alléliques chez les personnes atteintes de problèmes de santé mentale en Ontario, au Canada
Introduction: Drug metabolism is primarily carried out by the cytochrome P450 (CYP) family of enzymes in the liver. Based on an individual's diplotype, they can be classified into poor (PM), intermediate (IM), normal (NM), rapid (RM) or ultrarapid (UM) metabolizers. Here, we show the distribution of allele frequency and metabolizer status across ancestries for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 in a cohort from Ontario, Canada. Methods: Patients currently taking or starting a psychotropic drug ( N = 8,280) were enrolled. Patients self-reported their ancestry, and DNA was analysed for the CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 genes using a commercial pharmacogenetic test and metabolizer status was assigned using ClinPGx as a reference. Results: The cohort was primarily of European ancestry (70%), followed by individuals with mixed ancestry (9.3%). The combined frequency of PMs and UMs, representing the extremes of enzyme activity, was highest for CYP2C19 and CYP2D6, with this frequency being approximately 8% for each enzyme. The frequency varied considerably by ancestry, with up to 24% of individuals of Caribbean descent being CYP2C19 PMs or UMs, for example, compared to only 7% among those of Latin, Central and South American ancestry. Of the entire sample, only 5.1% were NMs across all enzymes, meaning 94.9% of individuals had a non-NM status and would benefit from pharmacogenetic testing. Conclusion: Overall, this study provides a useful reference for variations in the CYP family of genes in the population of Ontario, Canada.
- 4 June 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (9) , 703-711
Distribution of Cytochrome P450 Metabolizer Status and Allelic Variants in Individuals with Mental Health Disorders in Ontario, Canada: Répartition du statut métabolique du cytochrome P450 et des variantes alléliques chez les personnes atteintes de problèmes de santé mentale en Ontario, au Canada
Introduction: Drug metabolism is primarily carried out by the cytochrome P450 (CYP) family of enzymes in the liver. Based on an individual's diplotype, they can be classified into poor (PM), intermediate (IM), normal (NM), rapid (RM) or ultrarapid (UM) metabolizers. Here, we show the distribution of allele frequency and metabolizer status across ancestries for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 in a cohort from Ontario, Canada. Methods: Patients currently taking or starting a psychotropic drug ( N = 8,280) were enrolled. Patients self-reported their ancestry, and DNA was analysed for the CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4 and CYP1A2 genes using a commercial pharmacogenetic test and metabolizer status was assigned using ClinPGx as a reference. Results: The cohort was primarily of European ancestry (70%), followed by individuals with mixed ancestry (9.3%). The combined frequency of PMs and UMs, representing the extremes of enzyme activity, was highest for CYP2C19 and CYP2D6, with this frequency being approximately 8% for each enzyme. The frequency varied considerably by ancestry, with up to 24% of individuals of Caribbean descent being CYP2C19 PMs or UMs, for example, compared to only 7% among those of Latin, Central and South American ancestry. Of the entire sample, only 5.1% were NMs across all enzymes, meaning 94.9% of individuals had a non-NM status and would benefit from pharmacogenetic testing. Conclusion: Overall, this study provides a useful reference for variations in the CYP family of genes in the population of Ontario, Canada.
- Open Access
- 5 September 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 74-79
GenoStaR : An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety. Central to this process is accurate genotype‐to‐phenotype translation, especially for the CYP enzyme family, which metabolizes 70–80% of clinically used drugs. To address this, we have developed GenoStaR, an R package that converts genotypes into star alleles and predicts the associated metabolizer status for major cytochrome P450 genes— CYP1A2 , CYP2B6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 , and CYP3A5 . GenoStaR assigns star alleles using single‐nucleotide polymorphisms, insertion–deletion variants, and structural variants. Given genotype data, GenoStaR uses comprehensive allele definition tables to determine diplotypes, activity scores, and predicted metabolizer status. The tool accounts for complex scenarios, including CYP2D6 copy number variations, using a tiered matching strategy and structural variant detection. We evaluated GenoStaR using two datasets. The first from the Centre for Addiction and Mental Health Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study ( n = 8,287), which included genotyping data, along with star allele information from a commercial pharmacogenetic test. The second, the Toronto Schizophrenia sample ( n = 188), with in‐house genotype data and manually validated star alleles. GenoStaR achieved 100% concordance in diplotype calls across both datasets. GenoStaR offers a reliable, efficient, and accurate solution for converting genotypes into star alleles and predicting CYP‐related metabolizer status. Its performance on a large validation dataset highlights its potential to enhance pharmacogenomic testing in clinical settings.
- 5 September 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (1) , 74-79
Open AccessGenoStaR : An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety. Central to this process is accurate genotype‐to‐phenotype translation, especially for the CYP enzyme family, which metabolizes 70–80% of clinically used drugs. To address this, we have developed GenoStaR, an R package that converts genotypes into star alleles and predicts the associated metabolizer status for major cytochrome P450 genes— CYP1A2 , CYP2B6 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 , and CYP3A5 . GenoStaR assigns star alleles using single‐nucleotide polymorphisms, insertion–deletion variants, and structural variants. Given genotype data, GenoStaR uses comprehensive allele definition tables to determine diplotypes, activity scores, and predicted metabolizer status. The tool accounts for complex scenarios, including CYP2D6 copy number variations, using a tiered matching strategy and structural variant detection. We evaluated GenoStaR using two datasets. The first from the Centre for Addiction and Mental Health Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study ( n = 8,287), which included genotyping data, along with star allele information from a commercial pharmacogenetic test. The second, the Toronto Schizophrenia sample ( n = 188), with in‐house genotype data and manually validated star alleles. GenoStaR achieved 100% concordance in diplotype calls across both datasets. GenoStaR offers a reliable, efficient, and accurate solution for converting genotypes into star alleles and predicting CYP‐related metabolizer status. Its performance on a large validation dataset highlights its potential to enhance pharmacogenomic testing in clinical settings.